Personalized immunosuppression with leading organ transplant therapy may optimize patient care

... Monitoring the level of CellCept® (mycophenolate mofetil) in a patient's blood in the months following an organ transplant may enable physicians to identify the precise amount of drug needed by each patient to prevent organ rejection without increasing toxicity, thereby optimizing efficacy and tolerability of the drug over time... click link for more info. ...